In particular, the claims cover include transgenic NKs expressing CCR7 and CD16a (HA–CD16). The treatment methods also include dependent claims where the transgenic NK cells are coadministered with a monoclonal antibody therapeutic (e.g., rituximab). CCR7 is a chemokine receptor (chemokine (C—C motif) receptor 7) known to direct cellular migration to secondary lymphoid tissues, including lymph nodes where hematological malignancies such as diffuse large B cell lymphoma (DLBCL) reside. Normally, CCR7 is expressed by only a small subset of resting primary NK cells.

CD16 includes Fc receptors FcyRIIIa (CD16a) and FcyRIIIb (CD16b) found on the surface of natural killer (NK) cells and other leukocytes. CD16a binds to the Fc tail of IgG antibodies which then activates the NK cell for antibodydependent cellular toxicity (ADCC). Human wild type CD16 has a relatively low affinity for IgG1 antibodies. However, a single nucleotide polymorphism (SNP rs396991) in the CD16a gene (F to V at position 158; referred to hereafter as HA-CD16) results in substantially higher IgG1 affinity and superior NK mediated ADCC.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive licenses, both the one granted for the evaluation period and if converted into a full exclusive patent commercialization license, will be royalty bearing. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Heart, Lung, and Blood Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. Dated August 5, 2020. **Michael Shmilovich,** Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute. [FR Doc. 2020–17703 Filed 8–12–20; 8:45 am] **BILLING CODE 4140–01–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; PAR19–202: High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)—Hematological Diseases.

Date: September 28, 2020.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Blvd., Bethesda, MD 20892 (Video Meeting).

Contact Person: Najma S. Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7349, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8894, *begumn@niddk.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: August 7, 2020.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–17677 Filed 8–12–20; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Nursing Research.

The meeting will be open to the public as indicated below.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Nursing Research.

Date: September 15, 2020.

Open: 11:30 a.m. to 1:30 p.m.

Agenda: Discussion of Program Policies and Issues.

Place: https://videocast.nih.gov/ watch=38169, Bethesda, MD 20892 (Virtual Meeting).

Closed: 2:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, One Democracy Plaza, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kay Wanke, Acting Executive Secretary, National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, One Democracy Plaza, Bethesda, MD 20817, (301) 402–0036, *kay.wanke@nih.gov*.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: www.nih.gov/ ninr/a_advisory.html, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

Dated: August 10, 2020.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–17743 Filed 8–12–20; 8:45 am] BILLING CODE 4140–01–P